(116 days)
Not Found
No
The summary describes a surgical system for cataract and vitrectomy procedures with software and hardware revisions, but there is no mention of AI or ML capabilities, image processing, or data sets typically associated with AI/ML development.
Yes
The device is described as an ophthalmic microsurgical system intended for the emulsification and removal of cataracts, and anterior and posterior segment vitrectomy, which are medical procedures to treat specific conditions.
No
The device is intended for the emulsification and removal of cataracts and vitrectomy, which are surgical procedures, not diagnostic ones. It performs therapeutic functions rather than identifying or characterizing diseases.
No
The device description explicitly states that the system incorporates "software revisions and minor hardware changes," indicating it is not solely software. It also mentions the use of disposable packs and handpieces, which are hardware components.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use clearly describes a surgical system for performing procedures on the patient (emulsification and removal of cataracts, vitrectomy, etc.). IVDs are used to examine specimens from the body (like blood, urine, tissue) to provide information about a person's health.
- Device Description: The description reinforces that it's a microsurgical system used in anterior and posterior segment surgery.
- Lack of IVD Characteristics: There is no mention of analyzing biological samples, reagents, or providing diagnostic information based on laboratory tests.
The device is a surgical instrument used for treatment, not for in vitro diagnosis.
N/A
Intended Use / Indications for Use
The Bausch & Lomb Stellaris® Vision Enhancement System is intended for the emulsification and removal of cataracts, anterior and posterior segment vitrectomy. The system is designed for use in both anterior and posterior segment surgeries. It provides capabilities for phacoemulsification, irrigation/aspiration, bipolar, coaxial, and bipolar coagulation, viscous fluid injection/removal and air/fluid exchange operations. Use only Bausch & Lomb disposable packs and handpieces designated for use with the system.
Product codes
HQC, HQE
Device Description
The Bausch & Lomb Stellaris® Vision Enhancement System is an integrated ophthalmic microsurgical system designed for use in anterior segment surgery including phacofragmentation and vitreous aspirating and cutting- anterior vitrectomy.
The system is based on the technology and the performance of the existing Stellaris® system, and this special 510(k) incorporates software revisions and minor hardware changes. There is no change in the intended use or indications for use of the system.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
Safety tests of the Stellaris Vision Enhancement System have demonstrated its compliance with applicable requirements of the following standards:
- IEC 60601-1: Edition 3: 2007 Medical Electrical Equipment Part 1: General Requirements for . Safety
- . IEC 60601-1-2: Edition 3:2007-03 Medical Electrical Equipment - Part 1: General Requirements for Safety 2. Collateral Standard: Electromagnetic Compatibility - Requirements and Tests
Software changes were verified and validated in accordance with the Bausch & Lomb software quality procedures which comply with EN62304.
The Stellaris® Vision Enhancement System passed all of the above tests with no exceptions. This testing demonstrates that the functional requirements have been met and that the modified device is equivalent to the predicate device.
Key Metrics
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 886.4670 Phacofragmentation system.
(a)
Identification. A phacofragmentation system is an AC-powered device with a fragmenting needle intended for use in cataract surgery to disrupt a cataract with ultrasound and extract the cataract.(b)
Classification. Class II.
0
BAUSCH + LOMB
See better. Live better.
Section 8-510(k) Summary
1. General Information
| Submitter: | Contact Person: |
|---|---|
| Bausch & Lomb Inc. | Timothy W Capehart |
| 3365 Tree Court Industrial Blvd. | 636-226-3017 (Office) |
| St. Louis MO 63122 | 636-226-3245 (Fax) |
| General Telephone: 636-226-3017 | Timothy.Capehart@bausch.com |
| Summary Preparation Date: | |
| October 17, 2013 |
- Names
| Device Name(s): | Stellaris® Vision Enhancement System |
|---|---|
| Classification Name(s): | Phacofragmentation Unit, Vitreous Aspiration and Cutting Instrument |
| Common Name: | Ophthalmic surgical system for cataract and vitreo-retinal surgery |
| CFR References: | 21 CFR 886.4670, 21 CFR 886.4150 |
| Product Codes: | HQC, HQE |
3. Predicate Devices
- K082473 Stellaris® Microsurgical System .
- K063331 Stellaris ® Microsurgical System .
- K 101325 -- Stellaris ® PC Vision Enhancement System .
4. Product Description
The Bausch & Lomb Stellaris® Vision Enhancement System is an integrated ophthalmic microsurgical system designed for use in anterior segment surgery including phacofragmentation and vitreous aspirating and cutting- anterior vitrectomy.
The system is based on the technology and the performance of the existing Stellaris® system, and this special 510(k) incorporates software revisions and minor hardware changes. There is no change in the intended use or indications for use of the system.
5. Indications for Use
Indications for Use (same as K082473):
The Bausch & Lomb Stellaris® Vision Enhancement System is intended for the emulsification and removal of cataracts, anterior and posterior segment vitrectomy. The system is designed for use in both anterior and posterior segment surgeries. It provides capabilities for phacoemulsification, irrigation/aspiration, bipolar, coaxial, and bipolar coagulation, viscous fluid injection/removal and air/fluid exchange operations. Use only Bausch & Lomb disposable packs and handpieces designated for use with the system.
FEB 1 4 2014
1
BAUSCH + LOMB
See better. Live better.
6. Summary of Technological Characteristics
The technological characteristics of the Stellaris Microsurgical system are substantially equivalent to those of the predicate device.
| Characteristic | Stellaris® Vision Enhancement System | K082473/K063331
Stellaris® Microsurgical System |
|----------------------------|-----------------------------------------------|----------------------------------------------------|
| Product Code | HQC, HQE | HQC, HQE |
| Regulation | 21 CFR 886.4670, 21 CFR 886.4150 | 21 CFR 886.4670, 21 CFR 886.4150 |
| Intended Use | Intended for use in ophthalmic
procedures | Intended for use in ophthalmic procedures |
| Indications for Use | Exactly the same as K082473 | See K082473 |
| User interface | LCD touch screen | LCD touch screen |
| Device
activation | footswitch | footswitch |
| Electrical
requirements | 90-130 VAC, 50/60 Hz
200-240 VAC, 50/60 Hz | 90-130 VAC, 50/60 Hz
200-240 VAC, 50/60 Hz |
7. Safety and Effectiveness Information
The review of the indications for use and technical characteristics provided demonstrates that the Stellaris® Vision Enhancement System is substantially equivalent to the predicate device and is safe and effective for the emulsification and removal of cataracts, anterior and posterior segment vitrectomy.
Brief Summary of Nonclinical Tests and Results 8.
Safety tests of the Stellaris Vision Enhancement System have demonstrated its compliance with applicable requirements of the following standards:
- IEC 60601-1: Edition 3: 2007 Medical Electrical Equipment Part 1: General Requirements for . Safety
- . IEC 60601-1-2: Edition 3:2007-03 Medical Electrical Equipment - Part 1: General Requirements for Safety 2. Collateral Standard: Electromagnetic Compatibility - Requirements and Tests
Software changes were verified and validated in accordance with the Bausch & Lomb software quality procedures which comply with EN62304.
The Stellaris® Vision Enhancement System passed all of the above tests with no exceptions. This testing demonstrates that the functional requirements have been met and that the modified device is equivalent to the predicate device.
9. Conclusion
The Stellaris® Vision Enhancement System shares identical indications for use, similar design features. and functional features with, and thus is substantially equivalent to, the predicate device.
2
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized depiction of an eagle or bird-like figure with three curved lines representing its wings or body. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES-USA" is arranged in a circular fashion around the emblem.
Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
February 14, 2014
Bausch & Lomb, Inc. % Mr. Timothy W. Capehart Manager of Regulatory Affairs, Equipment and Instruments 3365 Tree Court Industrial Blvd. St. Louis, MO 63122
Re: K133242
Trade/Device Name: Stellaris® Vision Enhancement System Regulation Number: 21 CFR 886.4670, 21 CFR886.4150 Regulation Name: Phacofragmentation system Regulatory Class: Class II Product Codes: HQC, HQE Dated: December 13, 2013 Received: December 16, 2013
Dear Mr. Capehart:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies.
3
Page 2 - Mr. Timothy W. Capehart
You must comply with all the Act's requirements, including, but not limited to: Registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its tollfree number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Igdustry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
Kesia Y. Alexander -S
for Malvina B. Eydelman, M.D. Director Division of Ophthalmic and Ear, Nose and Throat Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
4
Indications for Use Statement
510(k) Number (if known): K133242
Device Name: Stellaris® Vision Enhancement System
Indications for Use :
The Bausch & Lomb Stellaris Vision Enhancement System device is intended for the emulsification and removal of cataracts, anterior and posterior segment vitrectomy. The system is designed for use in both anterior and posterior segment surgeries. It provides capabilities for phacoemulsification, irrigation/aspiration, bipolar, coaxial, and bipolar coagulation, vitrectomy, viscous fluid injection/removal and air/fluid exchange operations. Use only Bausch & Lomb disposable packs and handpieces designated for use with the system.
V Prescription Use (Part 21 CFR 801 Subpart D)
AND/OR
Over-The-Counter Use (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)